KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Retained Earnings (2016 - 2025)

West Pharmaceutical Services' Retained Earnings history spans 17 years, with the latest figure at $4.4 billion for Q4 2025.

  • For Q4 2025, Retained Earnings rose 1795.04% year-over-year to $4.4 billion; the TTM value through Dec 2025 reached $4.4 billion, up 1795.04%, while the annual FY2025 figure was $4.4 billion, 1795.04% up from the prior year.
  • Retained Earnings for Q4 2025 was $4.4 billion at West Pharmaceutical Services, up from $4.3 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $4.4 billion in Q4 2025 and bottomed at -$258.1 million in Q4 2024.
  • The 5-year median for Retained Earnings is $2.3 billion (2021), against an average of $1.7 billion.
  • The largest annual shift saw Retained Earnings tumbled 108.78% in 2021 before it skyrocketed 3227.22% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $2.5 billion in 2021, then rose by 21.62% to $3.0 billion in 2022, then tumbled by 104.81% to -$143.8 million in 2023, then tumbled by 79.49% to -$258.1 million in 2024, then surged by 1795.04% to $4.4 billion in 2025.
  • Per Business Quant, the three most recent readings for WST's Retained Earnings are $4.4 billion (Q4 2025), $4.3 billion (Q3 2025), and -$88.7 million (Q2 2025).